Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow MCK by emailGet an email when MCK pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MCK, unsubscribe in one click. Privacy
📣 What MCK Says Is Next
fourth quarter · “Document Exhibit 99.1 McKESSON REPORTS FISCAL 2026 FOURTH QUARTER AND FULL YEAR RESULTS, PROVIDES FISCAL 2027 GUIDANCE, AND REAFFIRMS LONG-TERM FINANCIAL GROWTH TARGETS IRVING, Texas, May 7, 2026 - McKesson Corporation (NYSE:MCK) today announced results for the fourth quarter and fiscal year ended March 31, 2026.”
Company press release, May 7, 2026 · SEC filing
fourth quarter · “Document Exhibit 99.1 MCKESSON CORPORATION ANNOUNCES FOURTH QUARTER FISCAL 2026 EARNINGS RELEASE DATE AND PARTICIPATION IN UPCOMING CONFERENCES IRVING, Texas, March 6, 2026 -- McKesson Corporation (NYSE: MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026.”
Company press release, Mar 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full MCK picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MCK and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.